Visual dysfunction is common in patients with Parkinson’s disease (PD). The objective of this study was to investigate the perceived impact of visual dysfunction and especially color vision loss on PD patients, and to identify retinal and disease factors associated with color vision. Thirty PD patients and thirty-four healthy controls were included. Participants performed the Farnsworth–Munsell Hue-100 test (FMT). Patients answered the National Eye Institute Visual Function Questionnaire (NEI-VFQ), Unified Parkinson’s Disease Rating Scale (UPDRS) assessment, and underwent optical coherence tomography with measurement of retinal nerve fiber layer, ganglion cell layer + inner plexiform layer (GCIPL), and outer nuclear and photoreceptor layer. Dopaminergic treatment was assessed as levodopa equivalent dose (LED). Vision domains significantly worse in PD patients compared to normative data were General Vision, Near Activities, Distance Activities, Vision-Specific Dependency, Driving, and Peripheral Vision. Worse NEI-VFQ total scores were associated with worse UPDRS, higher LED, and higher age, but not with FMT, visual acuity, or OCT measures. Only two patients (7%) reported problems with color vision. In contrast, patients performed significantly worse in the FMT than healthy controls and 17 (56.7%) patients were outside the 95th percentile of normative data. In multiple regression analyses, lower LED and higher age were associated with worse color vision in the FMT. PD patients are not aware of color vision deficits. Given the impact of color vision loss on everyday tasks in other conditions, future research should investigate the impact of vision deficits on disease burden in PD.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinson’s disease. Brain 132:1128–1145. https://doi.org/10.1093/brain/awp068
Armstrong RA (2015) Oculo-visual dysfunction in Parkinson’s disease. J Parkinsons Dis 5:715–726. https://doi.org/10.3233/JPD-150686
Beach TG, Carew J, Serrano G et al (2014) Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett 571:34–38. https://doi.org/10.1016/j.neulet.2014.04.027
Bertrand J-A, Bedetti C, Postuma RB et al (2012) Color discrimination deficits in Parkinson’s disease are related to cognitive impairment and white-matter alterations. Mov Disord Off J Mov Disord Soc 27:1781–1788. https://doi.org/10.1002/mds.25272
Bodis-Wollner I, Yahr MD (1978) Measurements of visual evoked potentials in Parkinson’s disease. Brain J Neurol 101:661–671
Bubl E, Kern E, Ebert D et al (2010) Seeing gray when feeling blue? Depression can be measured in the eye of the diseased. Biol Psychiatry 68:205–208. https://doi.org/10.1016/j.biopsych.2010.02.009
Büttner DT, Kuhn W, Patzold T, Przuntek H (1994) l-Dopa improves colour vision in Parkinson’s disease. J Neural Transm Parkinsons Dis Dement Sect 7:13–19. https://doi.org/10.1007/BF02252659
Büttner T, Kuhn W, Müller T et al (1995) Distorted color discrimination in “de novo” parkinsonian patients. Neurology 45:386–387
Cheung CYL, Leung CKS, Lin D, et al (2008) Relationship between retinal nerve fiber layer measurement and signal strength in optical coherence tomography. Ophthalmology 115:1347–51, 1351.e1–2. https://doi.org/10.1016/j.ophtha.2007.11.027
Fahn S, Elton R, Members of the UPDRS Development Committee (1987) The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. McMellam Health Care Information, Florham Park, pp 153–163
Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191
Franke GH, Esser J, Voigtländer A, Mähner N (1998) Der National Eye Institute Visual Function Questionnaire (NEI-VFQ) Erste Ergebnisse zur psychometrischen Ueberpruefung eines Verfahrens zur Erfassung der Lebensqualitaet bei Sehbeeintraechtigten. Z Für Med Psychol 7:178–184
Goodarzi Z, Mrklas KJ, Roberts DJ et al (2016) Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurology 87:426–437. https://doi.org/10.1212/WNL.0000000000002898
Haegerstrom-Portnoy G, Schneck ME, Lott LA et al (2014) Longitudinal increase in anisometropia in older adults. Optom Vis Sci 91:60–67. https://doi.org/10.1097/OPX.0000000000000114
Haug BA, Trenkwalder C, Arden GB et al (1994) Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 9:563–570. https://doi.org/10.1002/mds.870090510
Haug BA, Kolle RU, Trenkwalder C et al (1995) Predominant affection of the blue cone pathway in Parkinson’s disease. Brain J Neurol 118(Pt 3):771–778
Kinnear PR, Sahraie A (2002) New Farnsworth–Munsell 100 hue test norms of normal observers for each year of age 5–22 and for age decades 30–70. Br J Ophthalmol 86:1408–1411
Lin TP, Rigby H, Adler JS et al (2015) Abnormal visual contrast acuity in Parkinson’s disease. J Parkinsons Dis 5:125–130. https://doi.org/10.3233/JPD-140470
Mangione CM, Lee PP, Gutierrez PR et al (2001) Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119:1050–1058
Müller T, Kuhn W, Büttner T, Przuntek H (1997) Distorted colour discrimination in Parkinson’s disease is related to severity of the disease. Acta Neurol Scand 96:293–296
Müller T, Kuhn W, Büttner T et al (1998) Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson’s disease. J Neurol 245:659–664
Müller T, Meisel M, Russ H, Przuntek H (2003) Motor impairment influences Farnsworth–Munsell 100 Hue test error scores in Parkinson’s disease patients. J Neurol Sci 213:61–65
Price MJ, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology 42:887. https://doi.org/10.1212/WNL.42.4.887
Ridder A, Müller MLTM, Kotagal V et al (2017) Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 34:15–19. https://doi.org/10.1016/j.parkreldis.2016.10.006
Roth NM, Saidha S, Zimmermann H et al (2014) Photoreceptor layer thinning in idiopathic Parkinson’s disease. Mov Disord Off J Mov Disord Soc 29:1163–1170. https://doi.org/10.1002/mds.25896
Rudnicka AR, Mt-Isa S, Owen CG et al (2006) Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 47:4254–4261. https://doi.org/10.1167/iovs.06-0299
Sartucci F, Orlandi G, Lucetti C et al (2003) Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson’s disease. J Clin Neurophysiol Off Publ Am Electroencephalogr Soc 20:375–381
Schinzel J, Zimmermann H, Paul F et al (2014) Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol 14:31. https://doi.org/10.1186/1471-2377-14-31
Schmidt F, Zimmermann H, Mikolajczak J et al (2017) Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 11:45–50. https://doi.org/10.1016/j.msard.2016.11.008
Smith VC, Pokorny J, Pass AS (1985) Color-axis determination on the Farnsworth–Munsell 100-hue test. Am J Ophthalmol 100:176–182
Tagarelli A, Piro A, Tagarelli G et al (2004) Colour blindness in everyday life and car driving. Acta Ophthalmol Scand 82:436–442. https://doi.org/10.1111/j.1395-3907.2004.00283.x
Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 25:2649–2653. https://doi.org/10.1002/mds.23429
Uc EY, Rizzo M, Anderson SW et al (2009) Driving under low-contrast visibility conditions in Parkinson disease. Neurology 73:1103–1110. https://doi.org/10.1212/WNL.0b013e3181bacf6e
Walter SD, Ishikawa H, Galetta KM et al (2012) Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 119:1250–1257. https://doi.org/10.1016/j.ophtha.2011.11.032
Witkovsky P (2004) Dopamine and retinal function. Doc Ophthalmol Adv Ophthalmol 108:17–40
Yu J-G, Feng Y-F, Xiang Y et al (2014) Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One 9:e85718. https://doi.org/10.1371/journal.pone.0085718
This study was funded by German Research Foundation (DFG) Grant Exc. 257.
Conflict of interest
Alexander U. Brandt served on the scientific advisory board of the Vision study for Biogen; received travel funding and/or speaker honoraria from Novartis and Biogen; has patents pending from method and system for fovea morphometry, perceptive visual computing based postural control analysis, multiple sclerosis biomarkers, and perceptive sleep motion analysis; has consulted for Motognosis; and received research support from Novartis Pharma, Biogen Idec, BMWi, BMBF, and Guthy Jackson Charitable Foundation. Hanna Zimmermann received honoraria fees from TEVA and Bayer Healthcare. Timm Oberwahrenbrock received honoraria fees from TEVA and Bayer Healthcare. Justine Isensee reports no conflict of interest. Thomas Müller received speaker honoraria from Zambon and Bial. Friedemann Paul serves on a scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology® Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA.
About this article
Cite this article
Brandt, A.U., Zimmermann, H.G., Oberwahrenbrock, T. et al. Self-perception and determinants of color vision in Parkinson’s disease. J Neural Transm 125, 145–152 (2018). https://doi.org/10.1007/s00702-017-1812-x
- Color vision
- Tomography, optical coherence
- Parkinson disease
- Visual acuity